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Abstract
Background: Previous study has demonstrated that dietary taurine supplement protected rats
from impairments of synaptic plasticity induced by postnatal lead exposure. However, little is
known about the role of taurine in the presence of prenatal and perinatal lead exposure. We
investigated the possible effect of taurine supplement on prenatal and perinatal lead-induced
synaptic plasticity deficit and determined developmental periods critical for the effect of taurine.
Results: In the present study, taurine was administrated to prenatal and perinatal lead-exposed
rats in different developmental periods: from prenatal to weaning (Lead+PW-Tau), from weaning
to life (Lead+WL-Tau), and from prenatal to life (Lead+PL-Tau). We examined the input-output (I/
O) function, paired-pulse facilitation (PPF) and the long-term potentiation (LTP) of field excitatory
postsynaptic potential (fEPSP) in the hippocampal CA1 area of rats on postnatal days 18–25 (P18–
25) or days 60–75 (P60–75). We found that (1) on P18–25, taurine had no evident effect on I/O
functions and PPF ratios of lead-exposed rats but caused a 12.0% increase in the LTP amplitudes of
these animals; (2) on P60–75, taurine significantly elevated lead depressed I/O functions and PPF
ratios in Lead+PW-Tau and Lead+PL-Tau rats, but failed in Lead+WL-Tau rats. The amplitudes of
LTP of lead-exposed rats were all significantly increased by additional taurine supplement in any
developmental period compared with untreated rats. Thus, taurine appeared to have the most
effect during the prenatal and lactation periods and its effects on younger rats would not be
manifest until the adult life; and (3) the level of lead deposition in hippocampus was evidently
reduced by additional treatment of taurine in lead-exposed rats, compared with untreated rats.
Conclusion:  Taurine supplement can protect the adult rats from synaptic plasticity deficits
following prenatal and perinatal lead exposure, and the protective effects are critical for the
prenatal and lactation periods of lead-exposed rats.
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Background
Lead is a well-known environmental toxicant that induces
mental impairments in children and adolescents [1-4].
Whereas the cellular mechanisms underlying the manifes-
tation of lead-induced neurotoxicity remained elusive,
alterations in the properties of glutamatergic, cholinergic,
and dopaminergic neurotransmitters function and signal
transduction have been reported [5,6]. Besides, it is well
documented that the induction, expression, and mainte-
nance of long-term potentiation (LTP), a principal exper-
imental model used to study the role of synapses in
learning and memory, are impaired in hippocampal den-
tate gyrus (DG) and CA1 regions of animals exposed to
lead [7-11].
Taurine is an endogenous amino acid and is present at
concentrations second only to those of glutamate in the
mammalian central nervous system [12,13]. The essential
roles of this amino acid in development, osmoregulation,
and survival of neurons are well documented [14-16]. In
addition, some studies have proposed that taurine can
protect neural cells in some pathological conditions. For
instance, taurine attenuates Ca2+ influx and blocks the
excitatory neurotoxical cascades evoked by ischemia and
hypoxia [17-21]. Moreover, taurine protects against lead-
induced deficits of LTP in the DG areas of rats [22].
Recently, several clinical studies investigated the effects of
low-level prenatal and perinatal lead exposure on intellec-
tual development in children and found that mater-
derived lead exposure would have a more powerful and
lasting impact on neurobehavioral development of off-
spring than postnatal exposure [23-27]. Actually, even
very low level of maternal blood lead (10 µg/dL) may
induce intelligence quotient changes in the child [2]. The
vulnerability of the fetal brain to the lead toxicity at least
partly results from the immature blood brain barrier
(BBB) and the absence of tissue protein complexes that
can sequester lead [28].
By using electrophysiological methods, our previous
results showed that dietary taurine supplement protected
rats from the impairments of synaptic plasticity induced
by postnatal lead exposure [22]. However, little is known
about the possible role of taurine in the presence of fetal
lead exposure. In addition, no studies have evaluated the
developmental periods that are critical for proper protec-
tion from synaptic plasticity deficits in the rat pups with
prenatal and perinatal lead exposure. To investigate the
protective role of taurine in different developmental peri-
ods and to understand how this amino acid interacts with
lead, we conducted the experiments with hippocampal
slices and found that taurine was an effective drug to pro-
tect rats from synaptic plasticity deficits following prena-
tal and perinatal lead exposure. In addition, our data
indicated that taurine supplement during the prenatal and
lactation periods appeared to have the most potent pro-
tection against synaptic plasticity deficits in the adult rats
that had lead exposure during the fetal and neonatal age.
Results
Lead concentrations in hippocampus
Lead concentrations in hippocampi of the dams in differ-
ent developmental periods of postnatal days 18–25 (P18–
25) and days 60–75 (P60–75) are listed in Table 1 and
Table 2 respectively. In both developmental periods, there
were significant differences in lead concentrations
between Con and Lead groups (in both periods, p < 0.01),
but no significant differences were found between Con
and Con+Tau groups (in both periods, p > 0.05). At the
age of P18–25 days (Table 1), lead concentration in
Lead+PW-Tau group was significantly decreased relative
to the lead-only group, and statistically indistinguishable
from that of Con group (p > 0.05). At the age of P60–75
(Table 2), the lead levels in hippocampi of three lead-
exposed groups with additional taurine supplements were
significantly lower than that of Lead group (Lead+PW-
Tau: p < 0.01; Lead+WL-Tau: p < 0.05; Lead+PL-Tau: p <
0.01). No evident differences were found among
Lead+PW-Tau, Lead+PL-Tau and Con groups (p > 0.05).
These results demonstrate that 0.625% taurine supple-
ment in any of developmental periods significantly
reduced the concentration of lead in the brain. In
Lead+WL-Tau group, however, the lead concentration was
still significantly higher than that of Con group (p < 0.05).
P18–25 groups
Effect of taurine on I/O functions
To determine the effect of taurine on basal synaptic trans-
mission in the CA1 region, we first examined the input/
output (I/O) functions before the induction of LTP. The I/
O curves of Con, Con+Tau, Lead and Lead +PW-Tau
Table 1: Lead concentration in the hippocampus of P18–25 rats
Groups Con (n = 8) Lead (n = 10) Con+Tau (n = 8) Lead+PW-Tau (n = 7)
Lead concentration in 
hippocampus(µg/g)
0.357 ± 0.118 1.237 ± 0.554a 0.480 ± 0.148 0.654 ± 0.144b
All the values are expressed as mean ± SEM; the number of experiments is shown in brackets (n =); a significantly different from Con group (p < 
0.01); b significantly different from Lead group (p < 0.05) and statistically indistinguishable from Con group (p > 0.05). One-way ANOVA with the 
Bonferroni post hoc test were used for statistical analysis.BMC Developmental Biology 2007, 7:51 http://www.biomedcentral.com/1471-213X/7/51
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groups at age of P18–25 days are presented in Fig. 1A. We
found that the field excitatory postsynaptic potential
(fEPSP) slope was significantly depressed in Lead group
compared with that of Con group (Lead: n = 9; Con: n =
11, p < 0.01), indicating that the mater-derived lead expo-
sure had an effect on the baseline synaptic transmission in
the CA1 area of the hippocampus. However, there was no
significant difference between Con and Con+Tau groups
(Con+Tau: n = 9, p > 0.05). We next investigated the effect
of taurine on lead-exposed pups and no significant differ-
ence in I/O functions was found between Lead and
Lead+PW-Tau groups (Lead+PW-Tau: n = 10, p > 0.05).
Effect of taurine on PPF
To study the action of taurine on short-term synaptic plas-
ticity, we next examined the paired-pulse facilitation
(PPF) ratio by measuring fEPSP response to two stimuli
delivered at short inter-stimulus intervals (ISIs) from 10
to150 ms (Fig. 1C) and the waveform changes are
depicted in Fig. 1B. As shown in Fig. 1C, the average peak
facilitation was significantly lower in Lead group than that
in Con group (Lead: 160.5 ± 14.4%, ISI = 40 ms, n = 9;
Con: 190.4 ± 8.3%, ISI = 40 ms, n = 11; p < 0.01). We also
found that taurine supplement with the coexistence of
lead did not significantly alter the PPF ratio of Lead group
at the age of P18–25 days, although it appreciably
increased the peak facilitation of Lead group from 160.5 ±
14.4% to 166.3 ± 12.7% in Lead+PW-Tau group
(Lead+PW-Tau group: ISI = 50 ms, n = 10; p > 0.05). On
the other hand, the average peak facilitation of the control
rats was significantly decreased from 190.4 ± 8.3% to
148.8 ± 6.8% by taurine application to the intact fetus
(Con+Tau: 148.8 ± 6.8%, ISI = 50 ms, n = 9; p < 0.01).
Effect of taurine on LTP
Fig. 2 illustrates LTP in four P18–25 groups. After 20-min
baseline fEPSP recording, a high frequency stimulus (HFS,
100 Hz, 1 sec) was applied to induce LTP; fEPSPs were
recorded for more than 60 minutes after HFS. Fig. 2A
shows the waveform alterations before and after LTP
induction in P18–25 Con, Con+Tau, Lead and Lead+PW-
Tau groups, respectively. Fig. 2B shows the amplitudes of
LTP in these four groups. Notably, LTP was reduced to
122.6 ± 9.6% in Lead group compared with 175.1 ± 7.6%
in Con group (p < 0.01). There was no significant change
in the amplitudes of LTP between control and control
with a taurine supplement groups (Con: 175.1 ± 7.6%, n
= 9; Con+Tau: 181.1 ± 8.3%, n = 8; p > 0.05). However,
significant difference was found between Lead and Lead
+PW-Tau groups (Lead: 122.6 ± 9.6%, n = 8; Lead +PW-
Tau: 137.3 ± 5.3%, n = 9; p < 0.01). In fact, with a taurine
supplement throughout prenatal and lactation periods,
the LTP amplitude of lead-exposed group with taurine
supplement was 12.0% higher than that of the lead
exposed pups without any taurine supplement (p < 0.01),
but still lower than that of the controls (p < 0.01). These
results suggest that, whereas taurine protected the lead-
induced impairment of LTP in the CA1 area to some
extent, it can not entirely reverse the lead-induced depres-
sion shortly after the coexistence with lead.
P60–75 groups
Effect of taurine on I/O functions
As shown in Fig. 3A, the fEPSP slope in Lead group was
significantly decreased compared with that in Con group
(Lead: n = 9; Con: n = 9; p < 0.01). This suggests that lead
exposure during the prenatal and perinatal periods may
induce a further depression on baseline synaptic transmis-
sion in the CA1 area. Consistent with the results obtained
in younger groups, no significant difference in stimulus-
response curves was found between the P60–75 Con and
Con+Tau groups (Con+Tau: n = 8, p > 0.05), indicating
that the I/O functions of grown-up control rats were not
affected by taurine supplement. Fig. 3B illustrates the
effects of taurine on I/O functions of three lead-exposed
groups with dietary taurine supplements. Compared with
that of Lead, the stimulus-response curves of fEPSP slope
in these three follow-up groups were all significantly
increased by taurine administrations (Lead+PW-Tau: n =
9, p < 0.01; Lead+PL-Tau: n = 9, p < 0.01; Lead+WL-Tau: n
= 10, p < 0.01). However, no evident differences in stimu-
lus-response curves were found among the former two
groups and Con group (p > 0.05). As to the Lead+WL-Tau
group, the stimulus-response curve was significantly
lower than that of Con group (p < 0.05), indicating the
least augment of I/O function. This result demonstrates
Table 2: Lead concentration in the hippocampus of P60–75 rats
Groups Con (n = 8) Lead (n = 8) Con+Tau (n = 7) Lead+ PW-Tau (n = 7) Lead+ WL-Tau (n = 8) Lead+ PL-Tau (n = 8)
Lead 
concentration in 
hippocampus(µg/g)
0.249 ± 0.096 1.514 ± 0.64a 0.249 ± 0.143 0.475 ± 0.129b 0.929 ± 0.094c 0.502 ± 0.148b
All the values are expressed as mean ± SEM; the number of experiments is shown in brackets (n =); a significantly different from Con group (p < 
0.01); b significantly different from Lead group (p < 0.01) and statistically indistinguishable from Con group (p > 0.05); c significantly different from 
Lead (p < 0.01), Con (p < 0.01), Lead+PW-Tau (p < 0.05) and Lead+PL-Tau groups(p < 0.05). One-way ANOVA with the Bonferroni post hoc test 
were used for statistical analysis.BMC Developmental Biology 2007, 7:51 http://www.biomedcentral.com/1471-213X/7/51
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The effects of taurine on LTP induction in P18–25 groups Figure 2
The effects of taurine on LTP induction in P18–25 groups. 
(A) Representative traces were recorded of field excitatory 
postsynaptic potentials (fEPSPs) before (a) and 60 min after 
(b) HFS in Con, Con+Tau, Lead and Lead+PW-Tau slices. (B) 
LTP was induced by stimulation at 100 Hz for 1 sec. For the 
sake of clarity, points are plotted every 3 min here and in 
subsequent LTP figures. The amplitude in the Lead group was 
depressed compared with that of Con group (p < 0.01). 
There was no significant difference in LTP amplitude between 
Con and Con+Tau groups (p > 0.05). The LTP amplitude in 
Lead+PW-Tau group was 12.0% higher than that of Lead 
group (p < 0.01) but still lower than that of controls (p < 
0.01). (C) Histogram showing mean ± SEM percentage of 
fEPSP slope in 40–60 min normalized to the baseline 
response after HFS in Con, Con+Tau, Lead and Lead+PW-
Tau subjects (Con: 175.1 ± 7.6%, n = 9; Con+Tau: 181.1 ± 
8.3%, n = 8; Lead: 122.6 ± 9.6%, n = 8; Lead +PW-Tau: 137.3 
± 5.3%, n = 9). *p < 0.01, versus Con group. **p < 0.01, ver-
sus Lead group and p<0.01, versus Con group. One-way 
ANOVA with the Bonferroni post hoc test were used for sta-
tistical analysis.
The effects of taurine on I/O functions and PPF in P18–25  groups Figure 1
The effects of taurine on I/O functions and PPF in P18–25 
groups. (A) The I/O curve was significantly depressed in Lead 
group compared with that of Con group (Lead: n = 9, Con: n 
= 11, p < 0.01). There was neither significant difference in I/
O function between Con and Con+Tau groups (Con+Tau: n 
= 9, p > 0.05), nor a significant difference in I/O function 
between Lead and Lead+PW-Tau groups (n = 10, p > 0.05). 
(B) Representative traces of PPF at 40 ms ISIs in the four 
groups. (C) The PPF curves at varying from 10–150 ms in dif-
ferent groups. The average peak facilitation was significantly 
lower in Lead group than that in Con group (Lead: ISI = 40 
ms, n = 9; Con: ISI = 40 ms, n = 11; p < 0.01). Moreover, the 
Lead+PW-Tau group showed an insignificant augment com-
pared with the Lead group (Lead+PW-Tau: ISI = 50 ms, n = 
10; p > 0.05), but an evident reduction versus Con group (p 
< 0.01). The peak facilitation of the Con+Tau was signifi-
cantly lower than that of controls (Con+Tau: ISI = 50 ms, n = 
9; p < 0.01). The average peak facilitation was 190.4%, 
148.8%, 160.5% and 166.3% in the Con, Con+Tau, Lead and 
Lead+PW-Tau groups, respectively. One-way ANOVA with 
the Bonferroni post hoc test were used for statistical analysis.BMC Developmental Biology 2007, 7:51 http://www.biomedcentral.com/1471-213X/7/51
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The effects of taurine on I/O functions and PPF in P 60–75 groups Figure 3
The effects of taurine on I/O functions and PPF in P 60–75 groups. (A) The fEPSP slope in Lead group was significantly 
decreased compared with that in Con group (Lead: n = 9; Con: n = 9; p < 0.01). No significant difference in I/O function was 
found between Con and Con+Tau groups (Con+Tau: n = 8, p > 0.05). (B) The I/O curves in three taurine supplemented 
groups were significantly increased relative to Lead group (Lead+PW-Tau: n = 9, p < 0.01; Lead+PL-Tau: n = 9, p < 0.01; 
Lead+WL-Tau: n = 10, p < 0.01). No evident differences in I/O function were found among Lead+PW-Tau, Lead+PL-Tau and 
Con groups (p > 0.05). However, the I/O curve in Lead+WL-Tau group differed significantly from that of Con group (p < 0.05). 
(C) Representative traces of PPF at 40-ms ISI in the six groups. (D) The PPF curve at varying from 10–150 ms in each group. 
The mean peak facilitation was 12.6% lower in Lead than that in Con group (Lead: 139.8 ± 9.7%, ISI = 40 ms, n = 8; Con: 159.2 
± 8.1%, ISI = 50 ms, n = 11; p < 0.01). A significant decrease of peak facilitation in Con+Tau was observed compared with Con 
group (Con+Tau: 143.6 ± 7.8%, ISI = 40 ms, n = 9; p < 0.01). (E) The peak facilitation ratios in Lead+PW-Tau and Lead+PL-Tau 
groups were evidently enhanced compared with the Lead (Lead+PW-Tau: 166.7 ± 8.5%, ISI = 40 ms, n = 9, p < 0.01; Lead+PL-
Tau: 159.3 ± 7.5%, ISI = 40 ms, n = 9, p < 0.01), but were statistically indistinguishable from that of Con group (p > 0.05). In 
contrast, the PPF in Lead+WL-Tau group remained as low as that in Lead group (Lead+WL-Tau: 137.0 ± 8.3%, ISI = 40 ms, n = 
10; Lead: 139.8 ± 9.7%, ISI = 40 ms, n = 8; p > 0.05) and differed significantly from that of Con group (p < 0.01). One-way 
ANOVA with the Bonferroni post hoc test were used for statistical analysis.BMC Developmental Biology 2007, 7:51 http://www.biomedcentral.com/1471-213X/7/51
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that taurine supplement from weaning till life did not
reverse the lead-induced impairment of baseline synaptic
transmission.
Effect of taurine on PPF functions
On P60–75 days, the mean peak facilitation of lead-
exposed rats was 12.6% lower than that of Con group
(Lead: 139.8 ± 9.7%, ISI = 40 ms, n = 8; Con: 159.2 ±
8.1%, ISI = 50 ms, n = 11; p < 0.01), indicating a lasting
effect of prenatal and perinatal lead exposure on short-
term synaptic plasticity (Fig. 3D). We also investigated the
effects of taurine on the control rats. Consistent with the
results in younger groups, a significant decrease in the
peak facilitation in Con+Tau was observed compared with
Con group (Con+Tau: 143.6 ± 7.8%, ISI = 40 ms, n = 9; p
< 0.01; Fig. 3D). This result suggests that, for experimental
animals under normal conditions, the additional taurine
intake may exert some adverse effects on synaptic facilita-
tion. To further determine the developmental periods that
are critical for protecting against lead-induced deficits in
short-term synaptic plasticity, we analyzed the PPF of
three follow-up groups and the PPF of fEPSP slope in Con,
Lead, Lead+PW-Tau, Lead+WL-Tau and Lead+PL-Tau
groups are all demonstrated (Fig. 3E). The peak facilita-
tion ratios in Lead+PW-Tau and Lead+PL-Tau groups were
evidently greater than that in Lead group (Lead+PW-Tau:
166.7 ± 8.5%, ISI = 40 ms, n = 9, p < 0.01; Lead+PL-Tau:
159.3 ± 7.5%, ISI = 40 ms, n = 9, p < 0.01), both statisti-
cally indistinguishable from that of Con group (p > 0.05).
In contrast, the peak facilitation ratio in Lead+WL-Tau
group remained as low as that in Lead group (Lead+WL-
Tau: 137.0 ± 8.3%, ISI = 40 ms, n = 10; Lead: 139.8 ±
9.7%, ISI = 40 ms, n = 8; p > 0.05) and differed signifi-
cantly from that of Con group (p < 0.01). Fig. 3C shows
the waveform change in each group. These results demon-
strate that taurine supplement from prenatal to life or
from prenatal to weaning protected against the lead-
induced deficits of short-term synaptic plasticity effec-
tively. Contrarily, when it was applied to lead-exposed
pups after weaning, taurine did not show such an effect.
Effect of taurine on LTP
In the experiments centered on P18–25 days, taurine
failed to reverse the impaired LTP in Lead group com-
pared with untreated group. To further determine to what
extent taurine could exert its protective action and to eval-
uate the periods important for the protection of LTP, we
followed up the lead-exposed young groups which had
received taurine supplements in different developmental
periods. Over the postnatal period of 60–75 days, LTP of
Con, Con+Tau, Lead, Lead+PW-Tau, Lead+WL-Tau and
Lead+PL-Tau groups were examined (Fig. 4B, C, D) and
the waveform alterations before and after LTP induction
in each group are shown in Fig. 4A.
As shown in Fig. 4B, the LTP amplitude in P60–75 Lead
group was significantly decreased relative to Con group
(Lead: 117.1 ± 4.7%, n = 8; Con: 134.0 ± 5.4%, n = 9, p <
0.01), indicating an apparent maternal lead-induced
impairment of fEPSP LTP in the adult hippocampal CA1
area. Consistent with the results in P18–25 groups (Fig.
2B), there was no significant difference in LTP amplitudes
between the control and control with taurine supplement
group (Con: 134.0 ± 5.4%, n = 9; Con+Tau: 131.0 ± 4.0%,
n = 8, p > 0.05; Fig. 4C).
As shown in Fig. 4D, the LTP amplitudes in the Lead+PW-
Tau, Lead+WL-Tau and Lead+PL-Tau groups were all sig-
nificantly increased versus Lead group (Lead: 117.1 ±
4.7%, n = 8; Lead+PW-Tau: 143.3 ± 8.2%, n = 8;
Lead+WL-Tau: 131.2 ± 5.3%, n = 10; Lead+PL-Tau: 133.9
± 5.2%, n = 8; p < 0.01), statistically indistinguishable
from that of Con group (n = 9; p > 0.05). Additionally, we
found that there were no significant differences in LTP
amplitudes among these lead-exposed groups with varied
treatments of taurine. These results indicate that taurine
protected the lead-exposed rats from LTP deficits inde-
pendent of administration time.
Discussion
According to previous animal studies, even very low level
of lead exposure through the mothers can be deleterious
to rat pups [2]. Several clinical studies also have demon-
strated that increased maternal blood lead level is signifi-
cantly associated with a decrease in subsequent
intelligence, attention and other brain functions in infants
and adolescents [25,26,29]. Therefore, it is proposed that
the fetal brain is extremely susceptible to lead toxicity
[28], suggesting the most need for protection during the
prenatal and lactation periods.
Recently, accumulated evidence suggests that the primary
effects of lead are mediated, in part, by its oxidative dam-
age to cell membranes [30]. Lead has been proved to
induce lipid peroxidation and degradation of phospholi-
pids with the loss of membrane integrity in lead-burdened
tissues [31,32]. In addition, lead causes damage to the pla-
centa and disrupts the structure of blood-brain barrier
(BBB) in young animals [33-35]. Therefore, it may be sup-
posed that lead-induced oxidative damage also contrib-
utes to tissue injury in the blood-placenta barrier (BPB),
which restricts drug and toxic import through the placenta
to the fetus [36]. The increased permeability will then
consequently facilitate the accumulation of lead to the
brain [35].
Our results reveal that taurine cumbers the accumulation
of lead in the brain and acts most effectively during the
prenatal and lactation periods. These suggest a possible
membrane-protective action of taurine, on either BBB orBMC Developmental Biology 2007, 7:51 http://www.biomedcentral.com/1471-213X/7/51
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The effects of taurine on LTP induction in P60–75 groups Figure 4
The effects of taurine on LTP induction in P60–75 groups. (A) Representative traces were recorded from P60–75 Con, 
Con+Tau, Lead, Lead+PW-Tau, Lead+WL-Tau and Lead+PL-Tau slices before (a) and 60 min after (b) HFS was applied. (B) 
The LTP amplitude in Lead group was significantly decreased relative to Con group (Lead: 117.1 ± 4.7%, n = 8; Con: 134.0 ± 
5.4%, n = 9, p < 0.01). (C) No significant difference in LTP induction was found between Con and Con+Tau groups (Con: 134.0 
± 5.4%, n = 9; Con+Tau: 131.0 ± 4.0%, n = 8, p > 0.05). (D) The LTP amplitudes in the Lead+PW-Tau, Lead+WL-Tau and 
Lead+PL-Tau groups were all significantly increased relative to the Lead group (Lead: 117.1 ± 4.7%, n = 8; Lead+PW-Tau:143.3 
± 8.2%, n = 8; Lead+WL-Tau: 131.2 ± 5.3%, n = 10; Lead+PL-Tau: 133.9 ± 5.2%, n = 8; p < 0.01), but were statistically indistin-
guishable from that of Con group (Con: 134.0 ± 5.4%, n = 9; p > 0.05). Moreover, there were no significant differences in LTP 
induction among three lead-exposed with taurine supplement groups (p > 0.05). (E) Histogram showing mean ± SEM percent-
age of fEPSP slope in 40–60 min normalized to the baseline response after HFS in six P60–75 groups. *p < 0.01, versus Lead 
group, respectively. **p < 0.01, compared with Con group. One-way ANOVA with the Bonferroni post hoc test were used for 
statistical analysis.BMC Developmental Biology 2007, 7:51 http://www.biomedcentral.com/1471-213X/7/51
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BPB, counteracting entry of lead into the fetal brain. This
idea has been supported by the findings that taurine rein-
forces BBB through intensifying the integration of mem-
brane [37-39] and that taurine intercalates into the cell
membrane, thereby stabilizing it [40]. Taurine also acts on
the permeability of cell membrane to the ions [40,41].
Furthermore, the antioxidant effect of taurine has been
involved in the protection against lead-induced oxidative
damage to the cell membrane. In both culture cells and
rats, lead-induced abnormal augment of lipid peroxida-
tion is found to be decreased following taurine supple-
mentation. The membrane susceptibility to lipid peroxide
formation therefore seems to decline [42]. Unfortunately,
the direct contribution of taurine in BPB protection lacks
solid evidence, whereas taurine uptake activity in syncyti-
otrophoblast cells might indicate some related functions
[36]. An alternative explanation for the membrane-pro-
tective effects of taurine has been proposed based on tau-
rine-zinc interactions which are closely related to
development of structures such as the hippocampal for-
mation [43]. Taurine and zinc have been found to stabi-
lize the membrane and protect against lipid peroxidation
in the retina [44,45]. Moreover, a positive correlation of
zinc and taurine has already been observed in the hippoc-
ampus [43].
PPF, a short-term synaptic plasticity [46,47], has been
shown to be associated with increases in presynaptic Ca2+
levels and transmitter release [48-50]. In the past two dec-
ades, the residual calcium hypothesis [47] was used tradi-
tionally to explain PPF of central synaptic transmission
[51-54]. Ever since, the presynaptic residual Ca2+ as the
sole mechanism for PPF has been questioned [55,56].
Recently, many studies have agreed that a complete
understanding of the mechanisms of PPF should include
that the increases of transmitter release (induced by resid-
ual Ca2+) generate PPF and the responsivenesses of α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA) receptors (modified by postsynaptic Ca2+ and
Ca2+/calmodulin (CaM) signaling pathways) regulate PPF
magnitude [57-59]. Moreover, in CA1 neurons, the activ-
ities of CaM-KII and protein kinase C (PKC) are also
required in the PPF resulting from postsynaptic changes
[60,61]. In the present study, lead exposure significantly
decreased the PPF in CA1 area. This impairment may
attribute to several toxic effects of lead. First, lead blocks
voltage-dependent calcium channels and then reduces the
calcium influx [62]; second, lead changes Ca2+/CaM-
mediated neurotransmitter release [63]; and third, lead
can antagonize the activity of PKC at nanomolar concen-
trations [64].
In line with the experiments on postnatal lead-exposed
animals [22,65], our results suggest that prenatal and peri-
natal lead exposure impairs LTP induction. LTP, as a
measure of synaptic plasticity, is regarded as the neuronal
basis of learning and memory. In hippocampal CA1 area,
the induction of LTP could involve Ca2+ influx through
activated voltage-dependent Ca2+ channels that follows N-
methyl-D-aspartate (NMDA) receptor activation [66-69].
Furthermore, Ca2+ release from intracellular stores also
appears to be required to generate LTP [70,71]. Lead, the
recognized nerve poison, is known to disturb calcium
homeostasis by interfering with not only the extracellular
Ca2+ influx but also the Ca2+ release and uptake of intrac-
ellular calcium stores [72]. Lead-induced oxidative dam-
ages to critical biomolecules like lipids, proteins and DNA
have also been observed [73]. In addition, the lead-gluta-
matergic interactions have been proved by numerous elec-
trophysiological, biochemical and behavioral studies [74-
76].
When taurine was administrated to the lead-exposed ani-
mals in the present study, several mechanisms may be
involved in the protection against lead-induced deficits in
synaptic plasticity. First, as stated above, taurine seems to
have a promising antioxidant effect against oxidative
damages induced by lead [42]. In lead-poisoned rats, tau-
rine is able to increase glutathione level, reduce oxidative
stress and elevate the activity of superoxidate dismutase,
contributing to the protection of brain [30]; second, tau-
rine is a known regulator of calcium homeostasis. Under
pathologic conditions, such as ischemia and seizure, tau-
rine attenuates Ca2+ influx, and therefore counteracts the
elevation of intracellular Ca2+  concentration [77,78].
Additionally, taurine may directly act on the sarcoplasmic
reticulum and regulate Ca2+ release and uptake of intracel-
lular stores [79]; third, taurine potentiates presynaptic
NMDA receptors, consequently facilitating the excitability
of Schaffer-collateral fibres in rat hippocampal slices [80];
and finally, taurine is proposed to regulate the activity of
NMDA receptors by stimulating N-[1-(2-
thienyl)cyclohexyl]-piperidine (TCP) binding with phen-
cyclidine-binding (PCB) sites on the receptors [81].
Taurine, as we described earlier, has multiple functions in
the mammalian brain participating in volume regulation
[82], neuromodulation [83] and neural cell protection
[21], and it is also essential for neurodevelopment and
survival for neural cells [14,16]. Considering the complex
effects of this amino acid, it is hard for us to predict its
behaviors when taurine coexists with lead in immature
brains. In the present study, confusingly, we found the
behaviors of taurine were diverse between P18–25 and
P60–75 Lead+PW-Tau rats, which had received taurine
supplementations identically. Indeed, the protective role
of taurine manifested itself only in the older group. To
explain this discrepancy, one scenario we would like to
entertain is that when taurine and lead simultaneously
exist in the immature brain, its manipulations are com-BMC Developmental Biology 2007, 7:51 http://www.biomedcentral.com/1471-213X/7/51
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plex. Besides hampering the accumulation of lead in the
brain, taurine can exert various neuroprotective actions
simultaneously. On the other hand, taurine affects the
fetal brain from multiple aspects, including the interac-
tions with inhibitory amino acid neurotransmitter recep-
tors. It has been reported that taurine may act as
endogenous agonist at glycine receptors [84] and activates
γ-aminobutyric acid type A (GABAA) receptors in imma-
ture hippocampus [85]. Having been withdrawn from the
simultaneous exposure of taurine and lead, the grow-up
rats in the older group thus could recover their losses in
synaptic plasticity gradually. However, given that the
receptors changed dramatically during the development
in the rat hippocampus [86], the exact mechanism of tau-
rine in fetal brain is beyond certainty.
Definitely, taurine exposure from prenatal to life
depressed the PPF in the intact rats. However, cautions
needs to be exercised when interpreting this attenuation
as a decrease in presynaptic release probability, because
postsynaptic changes may also contribute to the alteration
in PPF [59]. Despite this problem, we speculate that an
indirect inhibitory effect of taurine in immature brains,
via its adverse interactions with GABAergic neurotrans-
mission at high concentrations [87], might partially
account for this change under basal conditions. This pos-
sibility, however, needs to be further assessed with more
specific procedures. In addition to this effect on PPF, other
negative effects at high taurine concentrations have also
been identified [88,89]. Therefore, even though taurine
acts protectively under various pathological conditions,
taken together, its negative influences may lead to an
assumption that application of excessive taurine to the
intact rats might be toxic.
On the other hand, it is noteworthy that the depression
happened to PPF occurred to neither LTP induction nor I/
O function under basal condition. This discrepancy might
be caused by a homeostasis mechanism regulated by tau-
rine. Taurine is a powerful regulator of calcium homeosta-
sis under conditions of low level of [Ca2+]i, as well as Ca2+
overload [90] and it may up-regulate the activity of
NMDA receptors [81]. It is now well established that, in
hippocampal CA1 area, the LTP induction at Schaffer-col-
lateral pathway is mainly due to the postsynaptic mecha-
nism depending on the activation of NMDA receptors and
an increase in postsynaptic Ca2+ concentration [91]. I/O
function, however, reflects not only the level of presynap-
tic neurotransmitter release but also the postsynaptic
receptor response. Hence, we hypothesize that taurine
may act positively at postsynaptic sites during synaptic
plasticity via enhancing Ca2+ concentration or receptor
response, thereby counteracting the inhibition of presyn-
aptic (or postsynaptic) neurotransmission. However, con-
sidering the limited understanding about the impact of
prolonged enhanced taurine levels on synaptic functions,
especially in immature brain, the mechanism of this dis-
crepancy remains to be elucidated.
Conclusion
In conclusion, taurine supplemented diet protects rats
against synaptic plasticity deficits following prenatal and
perinatal lead exposure. Most importantly, in this study,
taurine appears to have the most potent effect when it is
supplemented during the prenatal and lactation periods.
This suggests that prenatal and lactation periods are the
critical developmental periods for the protective action of
taurine. In developing countries, the pollution of lead
turns into a severe problem which emphasizes the proper
protection of taurine in the pregnant woman. Our data
also suggest the time window and dosage of taurine sup-
plement should be considered in the future community
intervention.
Methods
Experimental animals
The experiments were conducted on the offspring of six
groups of pregnant Wistar rats (70–80 days of age, 120–
200 g): control (Con), control with taurine diet
(Con+Tau), lead exposure (Lead), and three groups of
lead exposure dams with taurine diet during different
developmental periods (Lead+PW-Tau, Lead+WL-Tau and
Lead+PL-Tau). In the former two groups, the pregnant
dams received either distilled water or water with 0.625%
taurine from gestational day 1, with their offspring
switched to the same tap water (Con) or solution
(Con+Tau) at weaning on postnatal day 21. The latter four
groups were lead exposed via administration of 0.2%
(1090 ppm) solution of lead acetate in distilled drinking
water to pregnant dams from gestational day 1 through
weaning on postnatal day 21. Thus, the offspring acquired
lead only through their mothers. Concomitantly, 0.625%
taurine [92] were applied to Lead+PW-Tau, Lead+WL-Tau
and Lead+PL-Tau groups through drinking water (20 ml
per day) from prenatal to weaning, from weaning to life,
and from prenatal to life respectively.
Depending on developmental stage, the dams in
Lead+PW-Tau and Lead+PL-Tau groups were divided into
two subgroups for extracellular recording in CA1 area of
hippocampus. One subgroup was tested at the age of
P18–25 days and the other at P60–75 days. The pups at
P18–25 days in Lead+PW-Tau and Lead+PL-Tau groups
were administrated with lead and taurine almost in the
same manner (dosage and exposition phase). Hence, the
data in P18–25 Lead+PL-Tau group are not presented. For
any given experimental measure, equal numbers of
females and males were recruited and no more than two
pups were sampled from the same litter. All the animals
were maintained on NIH-07 chow (Ziegler Bros., Gardn-BMC Developmental Biology 2007, 7:51 http://www.biomedcentral.com/1471-213X/7/51
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ers, PA) to ensure consistent levels of mineral intake (see
Table 3 for the treatment of each group).
Hippocampus lead determination
Hippocampal lead determinations were made in litterma-
tes of the animals utilized for electrophysiology on the
day that recordings were made. After decapitation, two
hippocampi were collected. Lead concentrations were
measured by a plasmaQuad3 plasma mass spectrograph
(VG Elemental, UK) after the tissues were digested with an
organic tissue solubilizer.
Slice preparations and drugs
Care of animals and experiments were conducted in
accordance with the National Institutes of Health Guide-
line for the Care and Use of Laboratory Animals. Efforts
were made to minimize the number of animals used.
P18–25 (40–50 g) and P60–75 (100–180 g) rats were
anaesthetized with anhydrous diethyl ether and killed by
decapitation. Then the brain was quickly removed and
immersed in ice-cold artificial cerebrospinal fluid (ACSF)
saturated with 95% O2/5% CO2 and containing 124.0
mM NaCl, 3.0 mM KCl, 1.25 mM KH2PO4, 26.0 mM
NaHCO3, 2.0 mM MgSO4, 2.5 mM CaCl2, and 10.0 mM
glucose. Hippocampus was isolated and cut into 400 µM
thick transversal slices by a manual chopper. Before
recording, the slices were placed in an interface holding
chamber where they were maintained in oxygenated ACSF
at room temperature (21–25°C). After at least 1 hour, a
slice was transferred to a submersion-type recording
chamber (BSCHT Medical Systems, USA), in which it was
superfused continuously with 30–32°C oxygenated ACSF
at the rate of 1 ml/min. Drugs used in the present experi-
ments were all purchased from Sigma-Aldrich, USA.
Recording
To obtain evoked synaptic responses in CA1 area, Schaffer
collateral-commissural fibers were stimulated with electri-
cal pulses (0.1–0.6 mA, 0.2 ms, 0.05 Hz), applied through
bipolar microelectrodes located in stratum radiatum.
Evoked extracellular field potentials (fEPSPs) were
recorded with low resistance glass micropipettes filled
with 2 M NaCl (resistance 1–2 MΩ). At the start of each
experiment, a full input-output (I/O) curve was con-
structed. The stimulus intensities that yielded 1/2 and 2/3
of the maximal response were selected for baseline meas-
urements. PPF was tested by applying two pulses at differ-
ent intervals of 10–150 ms. After recording stable baseline
fEPSP responses for 20 minutes, LTP was induced by a
high-frequency stimulation (HFS; 100 Hz for 1 sec). After
that, testing with single shocks was continued for at least
60 minutes. The amplitudes of LTP were calculated by
averaging the percentage of post-tetanus data in 40–60
minutes compared with pre-tetanus baseline data. The
PPF values were calculated as EPSP2/EPSP1.
Data analysis
Data were recorded using Igor Pro 4.05 software (Wave
Metrics, OR, USA) and analyzed with Origin 7.5 (Origin-
Lab, MA, USA). The time scale in each experiment was
converted to time from the onset of the HFS. Results were
expressed as means ± SEM, n represents the number of
animals that were sampled. One-way ANOVA was per-
formed to determine whether there were significant differ-
ences followed by Bonferroni test as post hoc analysis; p <
0.01 indicated a significant difference.
Abbreviations
ACSF, artificial cerebrospinal fluid; AMPA, α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid; BBB, blood-
brain barrier; BPB, blood-placenta barrier; CaM, Ca2+/
calmodulin; DG, dentate gyrus; fEPSP, field excitatory
postsynaptic potential; GABAA, γ-aminobutyric acid type
A; HFS, high frequency stimulus; I.C.V, intracerebroven-
tricular; I/O, input-output; ISIs, inter-stimulus intervals;
LTP, Long-term potentiation; NMDA, N-methyl-D-aspar-
tate; PKC, protein kinase C; PPF, paired-pulse facilitation.
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